Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prothrombinex-VF is a human plasma-derived three-factor prothrombin complex concentrate (PCC) manufactured by CSL Behring. It contains concentrated vitamin K-dependent coagulation factors II (prothrombin), IX, and X, along with antithrombin III and heparin sodium, but notably contains minimal amounts of factor VII. It is primarily indicated for the rapid reversal of warfarin-induced anticoagulation (warfarin-associated coagulopathy) in patients experiencing major bleeding or requiring urgent surgery. Additionally, it is used for the treatment and perioperative prophylaxis of bleeding in patients with congenital deficiencies of factors II, IX, or X when specific single-factor concentrates are unavailable. By replenishing these essential components of the coagulation cascade, Prothrombinex-VF restores hemostatic potential and restores the patient's ability to form stable blood clots.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prothrombin complex.